HUMAN COMBINATION VACCINES MARKET ANALYSIS

Regional Analysis

Global Human Combination Vaccines market: Regional Insights

A boost in R&D activities and increasing technological advancements propel the market growth of human combination vaccine in North America. For instance, in 2019 three licensed DTaP combinations were readily available in North America for providing immunity against diphtheria, tetanus, and whooping cough (acellular pertussis) in children. These combination vaccines include Infanrix manufactured by GlaxoSmithKline, and Tripedia and Daptacel manufactured by Sanofi Pasteur. Also, booster combination vaccines Boostrix and Adacel are widely available for use in adults in North American region which drives the combination vaccine market growth in this region.

Additionally, the U.S government has been actively involved in vaccine awareness initiatives which is another factor that drives the growth of human combination vaccine. For instance, on 25^th May 2021, the Baker-Polite Administration partnered up with the Museum of Science, Boston with an aim of increasing access to COVID-19 vaccines. The administration announced USD 4.7 million investment for its Vaccine Equity Initiative.

Human combination vaccine market in Europe region is expected to flourish over the forecast period due to rise in research and development activities for providing better alternatives to the existing vaccines. For instance, in 2017, the U.K replaced the existing 5-in-1 DTaP-IPV/Hib vaccine with a better 6-in-1 combination vaccine which provides an additional immunity against hepatitis B.

Asia Pacific human combination vaccine market is anticipated to be the fastest growing due to rise in paediatric population and increasing prevalence of infectious diseases such as tetanus, whooping cough, polio, diphtheria, measles, chickenpox, and smallpox. For instance, according to Our World in Data report-2017, South Asia accounts for majority of new tetanus cases. In 2019, the World Health Organisation reported that in South East Asia around 52% deaths under the age of five happen during the neonatal period.